Pharmaceutical Executive Daily: Trump Administration Misses Deadline to Nominate Permanent CDC Director

Key Takeaways

• Administration missed CDC director nomination deadline
• CDC leadership void persists through most of term
• FDA granted accelerated approval for Avlayah, BBB‑crossing therapy
• Avlayah showed 91% biomarker reduction in trial
• CMS demands assumptions for Part B ASP reporting by April 30

Summary

The Trump administration failed to meet the 210‑day deadline to nominate a permanent CDC director, leaving the agency without confirmed leadership for most of the second term. Meanwhile, the FDA granted accelerated approval to Denali Therapeutics’ Avlayah, the first enzyme replacement therapy engineered to cross the blood‑brain barrier and treat the neurological aspects of Hunter syndrome. The approval was based on a Phase I/II trial showing a 91 percent reduction in cerebrospinal fluid heparan sulfate. A new CMS commentary warns that Part B drug manufacturers must now submit documented assumptions with quarterly ASP data by April 30, marking a substantive reporting shift.

Pulse Analysis

The absence of a confirmed CDC director creates a strategic blind spot at a time when the agency is navigating vaccine policy debates and preparing for the 2026 midterm election cycle. Without permanent leadership, the CDC’s ability to issue unified guidance, coordinate state partnerships, and respond swiftly to emerging health threats is compromised, potentially eroding public confidence and slowing critical interventions.

Denali Therapeutics’ Avlayah represents a watershed moment for rare‑disease therapeutics, being the first biologic designed to traverse the blood‑brain barrier and address Hunter syndrome’s neurological manifestations. The 91 percent biomarker reduction observed in a 47‑patient trial not only validates the platform’s scientific premise but also signals a broader shift toward CNS‑penetrant enzyme replacement therapies, a market segment poised for rapid growth as developers leverage similar delivery technologies.

CMS’s updated ASP reporting requirement forces Part B drug manufacturers to substantiate the assumptions underlying their price calculations, a move aimed at enhancing Medicare pricing transparency. By demanding documented rationale alongside quarterly data, the rule could reshape pricing strategies, increase administrative burdens, and prompt earlier engagement with payers. Companies that adapt quickly may gain a compliance edge, while laggards risk audit penalties and reputational damage.